Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 3, 2016. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of April 30, 2016:
- Total issued Ordinary Shares: 5,362,998,363 (25p each).
- Treasury Shares held: 491,505,950.
- Total voting rights: 4,871,492,413.
No material changes in financial performance or operational strategy are disclosed in this text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to capital structure notification.
Investor Verification Checklist
- Verify the total number of voting rights (4,871,492,413) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (491,505,950) as of April 30, 2016.
- Review the Company's Form 20-F for comprehensive financial performance data not included in this filing.